KNOWLEDGE BANK

Interviews

Accelovance China

President
Asia has had a dramatic spike in interest for medical research pharma advancement and global investment China and India are emerging as leaders in clinical trials They recruit patients faster cheaper and are better than Europe South America or the US because the economies are encouraging more research

Articles

Covid -19 and Nanoparticles

In field of Nanotechnology and Nano medicine there are large number of nanomaterials are used to deliver drug having properties like improving solubility extending formulations action different degrees of lipophilicity or hydrophilicity less toxicity and many more Chitosan based nanoparticles have been various applications

Research Insights

Oxidative stress antagonizes fluoroquinolone drug sensitivity via the SoxR-SUF Fe-S cluster homeostatic axis

The level of antibiotic resistance exhibited by bacteria can vary as a function of environmental conditions Here we report that phenazinemethosulfate PMS a redoxcycling compound RCC enhances resistance to fluoroquinolone FQ norfloxacin Genetic analysis showed that E coli adapts to PMS stress by making

Case Studies

Glucose Oxidase Stabilised in OxyzymeT - a commercial wound dressing

Partner nsense Ltd is a specialty wound care company that has developed a range of novel active hydrogelbased dressings OxyzymeT and IodozymeT which are capable of active delivery of oxygen iodine and nitric oxide to a wound site

Techno Trends

New Label Replacement Solution for Secondary Packaging

Labelling for secondary packaging traditionally involves selfadhesive thermal transfer printed labels The outer cases use large character inkjet printing to display the information As an economic and innovative alternative DataLase Technologies has introduced Casemark a new label replacement solution that gives of savings in cost for a medium volume line In addition...

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Incipient Biopharmaceutical Claims of Milk Derived Exosomes

Rakesh Kumar Tekade

Rakesh K. Tekade is a formulation researcher with of teaching and research experience. He has an explicit experience of over 10 years in teaching various modules for Ph.D, Masters & Bachelors students (@ Universities based in USA, UK, Malaysia, & India). He currently serving as Associate Professor at NIPER-Ahmedabad (An Institute of National Importance Government of India). Prior to this, Dr. Tekade was faculty at International Medical University, Kuala Lumpur, Malaysia. He took his postdoctoral trainings from UT Southwestern Medical Centre, Dallas, Texas, USA and University of Hawaii, Hilo, Hawaii, USA. He is a recipient of Commonwealth Fellowship at University of Central Lancashire, Preston, UK. Recently, Dr Tekade has been listed as Top 2% researcher in the field of Pharmacy and Pharmacology, by Stanford University, USA.

 

Nupur Vasdev

Nupur Vasdev is currently pursuing her PhD in the department of pharmaceutics from NIPER-Ahmedabad. She has completed M.S (Pharm.) in pharmaceutics from NIPER-Raebareli. She is currently working on targeted nano particulate drug delivery for obesity and cancer. Her research focus also includes surface modified exosome drug delivery for cancer and obesity.

 

Manisha Choudhary

Manisha Choudhary is currently pursuing her M.S. (Pharm) in Pharmaceutics at NIPER-Ahmedabad, India. She is currently working on aptamer decorated nanomaterials for improving the targeting. Her work majorly focuses on the improvement of the stability, targeting and robustness of aptamer conjugated nanomaterials for cancer treatment. Her work also focusses on the extraction of natural derived exosomes.

 

Suryanarayana Polaka

Suryanarayana Polaka is currently pursuing his PhD at NIPER-Ahmedabad, India. He is working in targeted drug delivery systems for the treatment of rheumatoid arthritis and wound healing. He also works on exosome mediated drug delivery. He co-authored 10 peer-reviewed publications in international journals, contributed > 7 international reference book chapters.

 

Kiran Kalia

Professor Kiran Kalia is a currently serving as Director and Professor at NIPER-Ahmedabad. Her work basically focused on the Proteomic markers for diabetic nephropathy, diabetic retinopathy and metal toxicity studies. Recently she started exploring the exosomes mediated drug delivery for delivering the genes for treating various ailments like cancer, wounds and diabetic nephropathy.

 

2

The Transformative Impact of AI on Regulatory Affairs

Yu Han

Yu Han, DPhil in Engineering Science from the University of Oxford, brings a rich background with experience at manufacturer, global regulatory affairs CRO, and AI sector. Her expertise spans the regulatory landscapes of Asia, the US, and the EU, providing a comprehensive understanding of global pharmaceutical regulations. Passionate about combining AI technology with healthcare, Yu excels in creating innovative engineering tools to advance medical solutions. Her work leverages engineering methodologies to unravel complexities in the medical listing process, streamlining the global product flow.     
 <p>&nbsp;</p>
Email: yu.han@eng.ox.ac.uk

 

3

Multi-Target Directed Ligands and Lipidomics Approach for Glioblastoma Drug Discovery

Dr. Stevan Pecic

Dr. Stevan Pecic is an assistant professor at the Department of Chemistry and Biochemistry at California State University, Fullerton. His main research interests and assignments are focused on the identification of novel inhibitors of enzymes involved in lipid metabolism and their evaluation as potential therapeutics in pain management.

 

Xiaohui Weng

Xiaohui Weng earned a bachelor’s in chemistry from Fordham University and recently completed her master’s degree working in Dr. Pecic medicinal chemistry lab at California State University, Fullerton. Her current research focuses on target identification for glioblastoma and the synthesis of new anti-cancer drugs.

 

Michael Gonzalez

Michael Gonzalez is a graduate student pursuing a master’s in chemistry at California State University Fullerton. Currently he also interns at a start-up biotech company, playing an important role in chemistry development for their high-throughput macrocyclic synthesis platform.

 

Arya Emami

Arya obtained his Hon. BSc. in Human kinetics from University of Guelph, where he completed a summer internship at Dr. Ghavami’s lab at University of Manitoba. Arya then pursued a double major from York University majoring in Neuropsychology. Arya’s research under the supervision of Dr. Ghavami resulted in four publications, and he has since been involved in the review and publication process of manuscripts in highly regarded journals. Arya is currently entering the second year of his Doctor of Dental Surgery program at the Faculty of Dentistry, University of Toronto.

Dr. Amir Barzegar Behrooz

Dr. Amir Barzegar Behrooz is a cancer researcher and postdoctoral fellow at the College of Pharmacy, University of Manitoba. His work focuses on various aspects of cancer biology, particularly glioblastoma. His work focuses on targeted cancer therapy, and theranostic targets in cancer cells via Onco-Multi-OMICS.

 

Dr. Rui Vitorino

Dr. Rui Vitorino, Principal Investigator at the University of Aveiro, specializes in OMICS, proteomics, and bioinformatics. His research on biofluids like saliva and urine aims to uncover disease pathways and biomarkers. Vitorino's multidisciplinary approach enhances early disease detection, influencing molecular and cell biology studies significantly.

 

Dr. Saeid Ghavami

Dr. Ghavami, an Associate Professor at the University of Manitoba, specializes in apoptosis, autophagy, and unfolded protein response regulation. With over 300 publications and numerous awards, he's globally recognised. Affiliated with institutions worldwide, he serves as Associate Editor for multiple scientific journals.

 

4

Approach for Producing Pharmaceuticals in Layer By Layer Fashion: Additive Manufacturing

Lakshmi usha Ayalasomayajula

Lakshmi usha Ayalasomayajula is an Assistant Professor in the Department of Pharmaceutical Technology at M.R. College of Pharmacy, India with 9 years of teaching and research experience. She has published 30 papers in international and national journals and has presented 20 papers in various conferences as author and co-author.

 

Earle Radha Rani

Earle Radha Rani is working as assistant professor in department of pharmaceutical technology, Maharajah’s College of Pharmacy, Andhra Pradesh, India. She has 7 years of teaching experience and has published over 30 research and review articles in several reputed national and international journals. Her areas of interest include novel drug delivery systems.

 

AVS Ksheera Bhavani

AVS Ksheera Bhavani is working as assistant professor in department of Pharmaceutical Biotechnology, Maharajah’s College of Pharmacy, Andhra Pradesh, India. She has about 10 years of teaching experience and has published over 10 research and review articles in several reputed national and international journals. Her areas of interest include novel drug delivery systems.

 

Kishore Pathivada

kishore pathivada ,an under graduate from Maharajah's college of pharmacy, Vizianagaram, during the year, 2017-21. I Qualified GPAT-2021 with AIR 705 and I also got qualified in NIPER JEE-2021 with AIR 62.Currently Iam pursuing my master's degree in Dept. of pharmaceutical Analysis at NIPER Mohali, Punjab which is one of the top most reputed colleges in INDIA in the field of Pharmaceutical Sciences and Research.

 

5

Six Sigma - Time, cost and product quality improvement

Ashwin Kuchekar

Ashwin Kuchekar is an Associate Professor and the Head of Career Services and Placement at the School of Pharmacy, Dr. Vishwanath Karad MIT-WPU in Pune. He completed his M. Pharm.in 2009 and Ph. D. in 2015. In 2012, he received the Senior Research Fellow (SRF) Award from the Council of Scientific Industrial and Research (CSIR).  He is a trained specialist in Lean Six Sigma Black Belt (LSSBB).  He has 7 years of industrial experience in reputed pharmaceutical companies such as Piramal, Lupin, and Abbott Healthcare. He has a unique blend of statistics and formulation development, Quality by Design with exposure to branded and generic product development. He has practical experience in the Design of Experiments and product formulation and process optimisation.

 

press releasesRead more...

Asia–US Clinical Data Collaboration Built on IHH's Clinical Data

Mitsui Co Ltd Mitsui Head Office Tokyo President and CEO Kenichi Hori has entered a service agreement with Oncoshot Pte Ltd Oncoshot on the utilization of Oncoshots proprietary clinical

Teijin, Teijin Regenet and Shinshu University Hospital Launch Joint Research to Strengthen CAR-T Cell Therapy Manufacturing Capabilities in Japan

Teijin Limited Teijin Regenet Co Ltd and Shinshu University Hospital today announced that they have entered into a joint research agreement regarding manufacturing technologies for cell and gene

VVMF, Australia’s First Viral Vector CDMO Receives TGA Manufacturing Licence

Viral Vector Manufacturing Facility Pty Ltd VVMF Australias first viral vector Contract Development and Manufacturing Organisation CDMO advises that the Therapeutic Goods Administration TGA

Oral insulin drug achieves a critical milestone

University of Sydney biotechnology spinout Endo Axiom is conducting its first study in human subjects to assess the safety and tolerability of different doses of oral insulin in healthy volunteers

Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies

Transcenta Therapeutics HKEX a global clinicalstage biopharmaceutical company with fully integrated capabilities in discovery RD and process development of antibodybased therapeutics

1cBio and Lee's Pharmaceutical Holdings Limited Enter into Exclusive Licensing Agreement to Develop and Commercialize 1cBio's PARP1 Inhibitor OC-3 for Oncology in Greater China

cBio a biopharmaceutical company focused on discovering and developing innovative therapies for serious and underserved conditions including oncology and metabolic diseases and Lees Pharmaceutical

EventsRead more...

14 - 15

Sep 2026

16th American DDF Summit

Omni Boston Hotel at the Seapo...

15 - 17

Sep 2026

COPD Drug Development Summit 2026

Street, Boston, MA 02210, USA

21 - 23

Sep 2026

21 - 23

Sep 2026

Cancer R&D World Conference

Hilton Garden Inn Miami Dolphi...

22 - 23

Sep 2026

22 - 24

Sep 2026

28 - 01

Sep 2026

LATEST NEWSRead more...

CordenPharma Expands Aseptic Fill-Finish Capacity to 500 Million Sterile Injectable Units Annually

CordenPharma is expanding its sterile injectable manufacturing capacity at its Caponago site in Milan Italy through a multiyear investment programme

Exegenesis Bio Enters into Collaboration with Modalis to Advance MDL-201 for Duchenne Muscular Dystrophy

Exegenesis Bio and Modalis Therapeutics have entered into a research collaboration and licence agreement to advance MDL an investigational treatment for Duchenne muscular dystrophy DMD

Schrödinger Forms Tectora Therapeutics to Advance Immunology and Inflammation Programmes

Schrdinger has announced the formation of Tectora Therapeutics The company was cofounded by Schrdinger New Enterprise Associates NEA and RA Capital Management

MannKind and Rose Pharma Partner to Develop Inhaled GLP-1 for Weight Management

MannKind and Rose Pharma have entered into a worldwide licensing and collaboration agreement to develop ROSE Technosphere an investigational inhaled GLP therapy for weight management

Rezubio Advances RZ-520 into Phase 1 Clinical Trial Following FDA and NMPA Clearances

Rezubio has announced the first cohort dosing in its Phase clinical trial of RZ following Investigational New Drug IND clearances from the US Food and Drug Administration FDA and Chinas National Medical

ZANVASTRO approved by FDA as first disease-modifying treatment for Alexander disease

Ionis Pharmaceuticals has received approval from the US Food and Drug Administration FDA for ZANVASTRO zilganersen to treat Alexander disease AxD in paediatric and adult patients